Atrial pressure and secretion of atrial natriuretic factor into the human central circulation  by Rodeheffer, Richard J. et al.
18
Atrial Pressure and Secretion of Atrial Natriuretic
Factor Into the Human Central Circulation
RICHARD J. RODEHEFFER, MD, ISSEI TANAKA, MD, TERUAKI IMADA, PHD,
ALAN S. HOLLISTER, MD, PHD, DAVID ROBERTSON, MD, TADASHI INAGAMI, PHD
Nashville, Tennessee
JACC Vol. 8, No. I
July 1986:18-26
Atrial natriuretic factor, a peptide found in mammalian
cardiac atria, has natriuretic and vasodilatoryproperties
that may be important in the regulation of intravascular
volume. To study factors related to its release in human
subjects, intracardiac pressures and plasma atrial na-
triuretic factor concentrations in the central circulation
were measured in 34 patients with a variety of cardio-
vascular disorders. Plasma atrial natriuretic factor con-
centration increased from the inferior vena cava to the
right atrium (76 ± 24 to 162 ± 37 pg/ml, p < 0.001)
and from the vena cava to the aorta (76 ± 24 to 177 ±
46 pg/ml, p < 0.001). Mean right atrial pressure was
positively correlated with atrial natriuretic factor con-
centration in the pulmonary artery (r =0.58, P < 0.001),
and mean pulmonary capillary wedgepressure was pos-
itively correlated with concentration in the aorta (r =
0.64, P < 0.001). In six patients whoseatrial natriuretic
Atrial distension has long been known to result in diuresis,
giving rise to the hypothesis that alterations in atrial pressure
are important in the regulation of circulatory volume (1).
Possible explanations for this phenomenon include the re-
lease of a circulating volume regulatory substance from the
atrium and the stimulation of central nervous system-me-
diated reflexes (2). Rat atrial tissue extracts were observed
by deBold et a1. (3) to produce diuresis and natriuresis when
injected into rats, suggesting that the atria produce material
with volume regulatory properties. Further studies (4-6)
indicated that the biologically active material was contained
in atrial but not ventricular myocytes of the rat.
Recent investigations (7,8) have disclosed the presence
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factor concentrations were measured at two different
levels of atrial pressure, increased atrial pressure was
accompanied by increased atrial natriuretic factor con-
centration in the pulmonary artery (p < 0.01) and aorta
(p < 0.01). Atrial natriuretic factor levels measured in
fresh myocardium from a patient undergoing cardiac
transplantation showedtissueconcentrations in the atria
500-fold higher than tissue concentrations in the ven-
tricles.
These data document that atrial natriuretic factor is
found in human atrial myocardium and suggest that it
may be released in response to increased atrial pressure.
Such a secretory release mechanism is consistent with
the hypothesis that atrial natriuretic factor plays a role
in the regulation of circulatory volume.
(J Am Coil CardioI1986;8:18-26)
of a peptide hormone, atrial natriuretic factor, in rat atrial
myocytes. This peptide has been purified and sequenced
(9-13), and has been shown in several mammalian species
to have potent natriuretic, diuretic and vasorelaxant prop-
erties, suggesting that it may playa role in the regulation
of circulatory volume (14-24). It has also been detected in
the rat hypothalamus and pontine tegmentum, and has been
shown to inhibit aldosterone and renin release (8,25-28).
There is strong evidence that elevated central venous pres-
sure is a stimulus for release of atrial natriuretic factor in
the rat, further supporting the hypothesis that atrial natri-
uretic factor is a volume regulatory hormone (29-32).
Atrial natriuretic factor has been detected in human plasma
and its primary structure has been determined (13,33-36).
Intravenous injection of synthetic human atrial natriuretic
factor has been shown to induce a marked diuresis and
natriuresis in human subjects (37,38). Anatomic localization
of atrial natriuretic factor has not, however, been confirmed
in humans, and physiologic stimuli regulating release of
atrial natriuretic factor have not been determined. Prelim-
inary reports (37,39) indicate that venous plasma atrial na-
0735-1097/86/$3.50
JACC Vol. 8, No.1
July 1986:18-26
RODEHEFFER ET AL.
ATRIALNATRIURETIC FACTOR
19
triuretic factor levels are increased after paroxysmal atrial
tachycardia, a clinical event known to be associated with
diuresis, and in some patients with circulatory failure.
To investigate the physiology of atrial natriuretic factor
release in humans we used a radioimmunoassay for this
peptide which was developed in our laboratory (25). We
measured pressure and plasma atrial natriuretic factor con-
centration in venous, arterial and intracardiac sites in pa-
tients exhibiting a variety of circulatory disturbances. Atrial
natriuretic factor tissue concentrations in all four cardiac
chambers were also measured for the first time in fresh
human myocardium to localize myocardial atrial natriuretic
factor.
Methods
Study patients. Patients undergoing right and left heart
catheterization for clinical reasons were considered eligible
for this study. Informed consent for blood sampling was
obtained as approved by the Vanderbilt Committee for the
Protection of Human Subjects. Patients were taking a variety
of medications at the time of the study including nitrates,
diuretic drugs, vasodilating agents, digitalis, beta-adrener-
gic blocking agents and calcium channel blockers. Patients
were premedicated with meperidine hydrochloride, pro-
methazine hydrochloride or diazepam before catheteriza-
tion.
The study group consisted of 34 patients (20 men and
14 women) with a mean age of 56 ± 2.5 years (range 18
to 79). Eighteen patients had coronary artery disease, seven
had dilated cardiomyopathy, two each had aortic regurgi-
tation, mitral stenosis and pulmonary hypertension and one
each had mitral regurgitation, aortic stenosis and Marfan's
syndrome without aortic regurgitation (Table 1). Patient 26
had had a porcine prosthetic aortic valve for 4 years, and
Patient 31 had had a porcine mitral valve for 10 years.
Procedures. With patients in the supine position a cath-
eter was placed in the descending aorta and right heart
catheterization was performed with a balloon-tipped flow-
directed catheter. Blood samples (10 ml) were obtained
simultaneously from the aorta and the inferior vena cava
between the renal veins and the diaphragm. Samples were
then drawn from the right atrium, right ventricle, pulmonary
artery and in the pulmonary capillary wedge position. Pul-
monary capillary wedge position was verified by oxygen
saturation, pressure waveform and fluoroscopy. Pressures
were measured in each position at the time samples were
obtained. Samples were obtained before injection of radio-
graphic contrast material. Data from one patient were ex-
cluded from analysis because of unreliable pressure mea-
surements.
One patient with a dilated cardiomyopathy (Case 24)
underwent orthotopic cardiac transplantation shortly after
entering the study. Samples of myocardium were obtained
from both atria and ventricles of the recipient's heart 10
minutes after surgical excision. Samples were frozen and
tissue atrial natriuretic factor concentration was determined
by a method previously described (40).
Preparation of human plasma samples. Blood samples
were drawn into plastic syringes through polyvinylchloride
and polyurethane catheters, and transferred to chilled sili-
conized glass tubes containing 1/10 volume of ethylenedi-
aminetetraacetic acid and aprotinin solution (pH 7.0). Final
concentrations of these protease inhibitors were 1 mg/ml
and 500 kallikrein inhibitor Vlml, respectively. One to three
milliliters of the plasma isolated by centrifugation were im-
mediately applied to 0.1 M acetic acid-washed Sep-Pak C18
cartridges to extract atrial natriuretic factor by a modification
of the previously described procedure (25). Recovery of this
extraction was 80%, and the data were corrected using this
factor.
Radioimmunoassay. Radioimmunoassay of extracted
human plasma samples was performed using the method
published (25) for the measurement of rat atrial natriuretic
factor. For application to human samples, human atrial na-
triuretic factor (amino acids 102 to 126) was radioiodinated
by the chloramine-T method and purified by passage through
a Sep-Pak cartridge, followed by high pressure liquid chro-
matographyon an octadecylsilane column (41). The 28 amino
acid human atrial natriuretic factor (amino acids 99 to 126)
was used for the standard. Rabbit antirat atrial natriuretic
factor (amino acids 102 to 126) antiserum (9), which cross-
reacts 35% with human atrial natriuretic factor (amino acids
99 to 126) on a molar basis, was utilized. The concentration
of atrial natriuretic factor was expressed as the amount of
human atrial natriuretic factor (amino acids 99 to 126). The
minimal detectable quantity of atrial natriuretic factor was
18 pg/ml plasma in early measurements and 12 pg/ml plasma
in later determinations. The intra- and interassay coefficient
of variation was 5.8 and 8.9%, respectively. The interassay
coefficient of variation was determined from 10 independent
assays of 100 pg/ml synthetic human atrial natriuretic factor
(amino acids 99 to 126). Plasma atrial natriuretic factor
levels below the level of sensitivity of the assay are ex-
pressed as the lowest detectable level, that is, 18 or 12
pg/ml. Mean venous atrial natriuretic factor in 25 normal
supine subjects had previously been determined to be 20 ±
4 pg/ml (42).
Materials. Aprotinin and Sep-Pak C18 cartridges were
purchased from Sigma Chemical Company and Waters As-
sociates, respectively. Human atrial natriuretic factor (amino
acids 102 to 126) was synthesized as described previously
(25). Human atrial natriuretic factor (amino acids 99 to 126)
was obtained from Peninsula Laboratories.
Statistical analysis. Data not normally distributed were
compared by the Wilcoxon signed ranks test or the Wilcoxon
nonpaired rank sum test. Normally distributed data were
compared with the paired t test. Regression analyses utilized
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Table 1. Characteristics of the 34 Patients in the Study Group
NYHA
Heart Left Atrial Diameter
Case Age (yr) & Sex Diagnosis Failure Class (mm) Medication
I 55M CAD I NA a, b, d, i
2 45F CAD I NA a, d
3 12M CAD II NA a, b, d, e, f
4 56M CAD II 47 a, b, g, j, s
5 68F CAD II 42 a, b, k, r
6 65M CAD III NA a, b, c, f
7 71M CAD I 45 a, b, d, g, h
8 53M CAD I NA b, c, d, e, h
9 71F CAD I NA c, e, 0
10 57M CAD I NA C, e, h
II 60M CAD II NA b, c, d,e, g, h, 0
12 61F CAD IV 40 b, c, d, e, f, g, h
13 60F CAD II NA b, c,d, g, h, n
14 52F CAD I 31 b, C
15 61M CAD I 39 b, C
16 53M CAD I NA b, c, d, f, h
17 56M CAD I NA b, c,d
18 63M CAD,MR III 44 a, b, g, h, j
19 61F CMP III 33 a, b, g, h, j, k
20 39M CMP II 51 c, g, j, p, q
21 70F CMP III 41 a, b, g
22 40F CMP II 46 b, c, d, f, g, h, j, m, q, s
23 39M CMP, CAD II 48 b, c, d, g, j, s, t
24 42M CMP IV 53 b, c, g, j, q
25 45M CMP II 45 b, c, j
26 61F AR IV 46 a, b
27 43M AR,MR IV 80 c, g, j, I, m
28 74M MR II 49 b, c, g, j, I
29 73F AS II 48 b, c, g, j
30 26M MS II 54 c
31 28F MS II 36 b, c,g
32 71F PHT III 54 a, b, g, h, j, k, n
33 79M PHT II 42 a, b
34 18F Marfan's syndrome I 20 c, e, k, 0, P
a = meperidine; b = promethazine; c = diazepam; d = calcium channel blocker; e = beta-blocker; f = aspirin; g = diuretic; h = nitrate; i =
dipyridamole; j = digoxin; k = levothyroxine; I = allopurinol; m = hydralazine; n = aminophylline; 0 = cimetidine; p = prednisone; q = captopril;
r = c1onidine; s = quinidine; t = amiodarone. AR = aortic regurgitation; AS = aortic stenosis; CAD = coronary artery disease; CMP = dilated
cardiomyopathy; F = female; M = male; MR = mitral regurgitation; MS = mitral stenosis; NA = not available; NYHA = New York Heart Association;
PHT = pulmonary hypertension.
the linear and multivariate least squares methods. Differ-
ences between groups were considered significant at a prob-
ability of less than 0.05.
Results
Plasma atrial natriuretic factor levels. Plasma atrial
natriuretic factor concentrations were measured in the 34
patients at six sites in the central circulation (Table 2). The
mean concentration was 76 ± 24 pg/ml (SEM) in the in-
ferior vena cava and rose to 162 ± 37 pg/ml in the right
atrium (p < 0.001). This significant increment from the
inferior vena cava was maintained in the right ventricle (167
± 41 pg/ml; difference between inferior vena cava and right
ventricle, p < 0.001) and in the pulmonary artery (173 ±
45 pg/ml; difference between inferior vena cava and pul-
monary artery, p < 0.00 1). In the pulmonary capillary wedge
position atrial natriuretic factor concentration fell to 110 ±
32 pg/ml (difference between pulmonary artery and pul-
monary capillary wedge concentrations, p < 0.001). Con-
centration in the descending aorta increased to 177 ± 46
pg/ml (difference between pulmonary capillary wedge and
aorta, p < 0.001). The net increase across the heart from
the inferior vena cava to aorta was from 76 ± 24 to 177
± 46 pg/ml (p < 0.001).
To examine the relation between atrialpressure and atrial
natriureticfactor concentration at a site distal to the atrium,
the correlation of pulmonary artery atrial natriuretic factor
concentration with mean right atrial pressure (MRAP) was
determined (Fig. 1). A statistically significant positive re-
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Table 2. Plasma Atrial Natriuretic Factor Concentrations and Hemodynamic Data in the 34 Patients
RA PA PCW Aorta
IVC
ANF ANF MRAP RV ANF ANF PAP ANF MPCWP ANF AOP
Case (pglml) (pglml) (mm Hg) (pg/ml) (pg/ml) (mm Hg) (pglml) (mm Hg) (pg/rnl) (mm Hg)
I 94 151 (0) 122 114 22/5 71 (3) 9 1 145175
2 18 62 (4) 23 18 22/8 18 (8) 18 140175
3 18 137 (0) 97 85 24/5 18 (3) 86 90/50
4 18 18 (4) 18 18 23112 18 (8) 18 125/60
5 18 18 (I) 18 18 28/12 18 (3) 18 165/60
6 18 240 (2) 205 148 40/ 15 145 (20) 239 115/60
7 18 18 (0) 20 18 20/5 18 (5) 24 120170
8 23 72 (4) 79 70 23/10 61 (9) 70 105/55
9 18 22 (0) 18 23 16/5 18 (3) 18 140175
10 12 12 (7) 30 35 38117 25 (10) 25 125/62
II 12 12 (3) 46 32 28/1 1 26 (8) 42 138/65
12 134 199 (4) 430 434 39/ 16 212 (12) 422 105/58
13 44 98 (3) 91 78 37117 54 (17) 71 185/95
14 12 29 (0) 13 25 15/6 12 (0) 136 125/80
15 12 59 (9) 12 43 28115 24 (13) 41 170/85
16 12 12 (2) 12 12 2318 12 (3) 12 115/50
17 12 12 (8) 12 12 27112 12 (10) 12 120/65
18 148 622 (12) 619 632 77/32 239 (28) 683 175/85
19 18 36 (0) 22 18 24/6 18 (0) 18 125/65
20 18 28 (0) 23 25 42115 18 (10) 23 115175
21 76 475 (0) 226 205 35/13 100 (9) 211 100145
22 18 131 (3) 18 18 37/15 18 (6) 18 90/55
23 456 540 (6) 744 720 45/20 456 (30) 564 105/55
24 197 445 (14) 360 365 48/28 258 (25) 337 95/68
25 12 12 (I) 12 16 26/8 12 (5) 12 118172
26 260 703 (10) 908 924 50/20 706 (16) 1.194 165/60
27 694 745 (12) 703 956 82140 722 (35) 829 100/58
28 44 130 ( 10) 182 168 75/28 60 (24) 184 135175
29 18 44 (4) 35 29 30113 22 (16) 48 120/45
30 18 134 (0) 208 155 35/18 118 (11) 160 105/65
31 12 12 (3) 12 12 31/14 12 (14) 12 118175
32 18 113 (9) 148 160 54/23 96 (14) 137 150175
33 55 121 (14) 181 254 70/30 NA (3) 220 115170
34 22 42 (0) 36 50 20/5 31 (3) 37 115/55
Mean 76 ± 24 162 ± 37 167 ± 41 173 ± 45 110 ± 32 177 ± 46
L p < 0.001..J L-- P < O.OOI-----l
I P < 0 .001
ANF = atrial natriuretic factor; AOP = aortic pressure; IVC = inferior vena cava; MPCWP = mean pulmonary capillary wedge pressure; MRAP
= mean right atrial pressure ; NA = not available; PA = pulmonary artery ; PAP = pulmonary artery pressure; PCW = pulmonary capillary wedge ;
RA = right atrium; RV = right ventricle . Pressures in parentheses are mean values.
lation was found (pulmonary artery atrial natriuretic factor tration by drug therap y, including the use of meperidine
== 25.6 ± 33.7 [MRAP]; r == 0 .58, P < 0.001). Similarly, hydrochloride in 13 patients.
Figure 2 shows the positive correl ation between the mean Effect of altered atrial pressure on atrial natriuretic
pulmonary capillary wedge pressure (MPCWP) and aortic factor levels. To further define the relation between atrial
atrial natriuretic factor concentration (aortic atrial natriuretic pressure and atrial natriuretic factor concentration, atrial
factor = -42.2 ± 19.4 [MPCWP] ; r = 0.64, p < 0.001). natriuretic factor levels and pressures in six patients were
Additional analysis indicated that the increment in plasma first obtained with the legs elevated 30°; the legs were then
atrial natriuretic factor concentration from inferior vena cava lowered for 7 minutes and repeat atrial natriuretic factor
to the aorta also correlated sign ificantly with mean right samples and pressures were obtained (Fig. 3, Table 3). Mean
atrial pressure (r = 0.44 , P < 0.01 ) and mean pulmonary right atrial pressure was 0.5 ± 1.1 mm Hg in the supine
capillary wedge pressure (r = 0.39, P = 0.02). Multivariate position and 3.2 ± l.l mm Hg with the legs elevated
analysis did not reveal an alteration in the relation between (p = 0.0l). Mean pulmonary capillary wedge pressure was
atrial pressures and plasma atrial natriuretic factor concen- 4.7 ± 1.7 mm Hg in the supine position and 7.3 ± 2.3
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Figure 1. Plasma atrial natriuretic factor (ANF)
level in the pulmonary artery as a function of
mean right atrial (RA) pressure.
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mm Hg with the legs elevated (p < 0.05). In every patient
elevation of atrial pressure was accompanied by a rise in
plasma atrial natriuretic factor concentration in the right
atrium, right ventricle, pulmonary artery and aorta. The
mean increase in plasma atrial natriuretic factor in the in-
ferior vena cava was 11.2 ± 4.7 pg/ml (p = NS), in the
right atrium 37.8 ± 6.2 pg/ml (p < 0.01), in the right
ventricle 30.5 ± 10.9 pg/ml (p < 0.01), in the pulmo-
nary artery 25.7 ± 5.8 pg/ml (p < 0.05) and in the aorta
39.5 ± 7.5 pg/ml (p < 0.01) (Fig. 3).
In 23 patients who underwent echocardiography, left
atrial diameter was measured in the parasternal long-axis
view. A positive relation was observed between left atrial
diameter and atrial natriuretic factor concentration in the
central circulation (Table 4).
The clinical severity of congestive heart failure was graded
using the New York Heart Association classification (43).
In patients with class I and II congestive symptoms the mean
aortic atrial natriuretic factor level was 78.4 ± 23.4 pg/ml;
in those with class III and IV symptoms the level was
452.3 ± 126.5 pg/ml (p < 0.001).
Patient 24. who had idiopathic dilated cardiomyopathy
r =0.64
p < 0.001
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Figure 2. Plasma atrial natriuretic factor 0~(ANF) level in the aorta as a function of a:
o
mean pulmonary capillary wedge (peW) -c
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Table 3. Plasma Atrial Natriuretic Factor Concentrations and Hemodynamic Data in Six
Patients During Posture Change
RA
RY PA pwe Aortalye
ANF ANF MRAP ANF ANF MPewp ANF
Patient* (pg/ml) (pg/ml) (mm Hg) (pg/ml) (pg/ml) (mmHg) (pg/ml)
A
Supine 12 12 (I) 12 16 (5) 12
Legs up 12 53 (4) 40 43 (8) 37
B
Supine 18 36 (0) 22 18 (0) 18
Legs up 18 48 (3) 52 58 (3) 58
e
Supine 18 28 (0) 23 25 (10) 23
Legs up 24 72 (5) 37 41 (17) 36
D
Supine 68 105 (5) 64 30 (9) 86
Legs up 84 159 (7) 139 43 (10) 148
E
Supine 116 207 (0) 178 191 (2) 208
Legs up 146 254 (0) 218 236 (2) 264
F
Supine 20 31 (-3) 37 37 (2) 15
Legs up 35 60 (0) 33 50 (4) 56
*Patient A = Patient 25; Patient B = Patient 19; Patient e = Patient 20; Patients D, E and F were studied
solely to ascertain postural changes and are not included in Tables 1 and 2. Abbreviations as in Table 2.
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and severe (class IV) heart failure, underwent orthotopic
cardiac transplantation. Fresh tissue specimens were ob-
tained from the resected recipient heart. In two samples of
right atrial tissue (not atrial appendage) the concentration
of atrial natriuretic factor was 41.8 JLg/g of wet tissue and
37.2 JLg/g of wet tissue, respectively. Left atrial myocar-
dium (not atrial appendage) contained 40.8 JLg/g wet tissue.
The concentration in the right ventricle was 0.094 JLg/g wet
tissue, and in the left ventricle it was 0.058 JLg/g wet tissue.
Correlation with systemic vascular resistance and renal
function. Because atrial natriuretic factor has been reported
to have vasorelaxant properties, the relation between total
systemic vascular resistance and aortic atrial natriuretic fac-
tor was examined. In this heterogeneous group of patients,
some of whom were taking vasodilating medication, no
significant correlation was found between plasma atrial na-
triuretic factor levels and total systemic vascular resistance
or cardiac output. Vascular resistance in specific vascular
beds, such as the renal circulation, was not determined in
this study. Plasma levels of atrial natriuretic factor in the
inferior vena cava, right atrium, pulmonary artery and aorta
showed no correlation with renal function as reflected by
serum creatinine levels.
Discussion
Atrial natriuretic factor has been detected in human plasma
and has been characterized as a fragment of a larger pre-
cursor peptide (8,13,33-35). Human data on tissue local-
ization of atrial natriuretic factor and the mechanisms of
atrial natriuretic factor release have not been previously
reported. Venous atrial natriuretic factor has been shown to
increase in a few patients after episodes of supraventricular
tachycardia, a clinical event often associated with diuresis
(37,39). Peripheral venous atrial natriuretic factor levels
have also been reported (37) to be elevated in patients with
clinical congestive heart failure. Hemodynamic variables
have not, however, been correlated with plasma atrial na-
triuretic factor levels. To localize the site of atrial natriuretic
factor release to the human heart and study hemodynamic
factors related to atrial natriuretic factor release, we used a
radioimmunoassay to measure atrial natriuretic factor in the
human central circulation in patients with a variety of cir-
culatory disorders (25).
Plasma atrial natriuretic factor concentrations. Our
data in humans document an increase in atrial natriuretic
factor from 76 ± 24 pg/ml in the inferior vena cava to
162 ± 37 pg/ml in the right atrium, confirming that atrial
natriuretic factor is released into the circulation at the level
of the right atrium. High concentrations of atrial natriuretic
factor were also detected in fresh human right atrial tissue,
further supporting the concept that the right atrium is an
important source of atrial natriuretic factor. Atrial natriuretic
factor may be released into the atrial venous circulation and
enter the right atrium through the coronary sinus (44) or it
may be released from the atrial endocardium by way of
Thebesian veins. Our data do not permit us to distinguish
between these two possibilities. Markedly increased con-
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AO = aorta; other abbreviations as in Table 2.
Table 4. Association of Left Atrial Diameter
With Plasma Atrial Natriuretic
Factor Concentration
Correlation
Site Coefficient p Value
IVC 0.64 0.001
RA 0.49 0.018
RV 0.44 0.038
PA 0.51 0.014
PCW 0.56 0.007
AO 0.41 0.05
in the right atrium (Table 2). There was no significant change
in atrial natriuretic factor concentration between the right
atrium (162 ± 37 pg/ml) and right ventricle (167 ± 41
pg/ml) or between the right ventricle and pulmonary artery
(173 ± 45 pg/ml), suggesting that no further atrial natri-
uretic factor is secreted from ventricular endocardium in
humans.
The significant decrease in atrial natriuretic factor con-
centration in the pulmonary capillary wedge position sug-
gests that the peptide may be degraded in the pulmonary
microcirculation; indeed, atrial natriuretic factor has been
shown to be more rapidly broken down in rat lung homog-
enates than in plasma (45). The finding that the aortic con-
centration of atrial natriuretic factor (177 ± 46 pg/ml) in-
creases to the level observed in the pulmonary artery suggests
the possibility that either atrial natriuretic factor is secreted
from the left atrial endocardium or plasma atrial natriuretic
factor concentrations are attenuated by the pulmonary cap-
illary sampling technique. The finding of high atrial natri-
uretic factor concentration in human left atrial tissue pro-
vides anatomic support for the former possibility, but the
present data cannot distinguish between these two expla-
nations. In future studies simultaneous sampling from the
pulmonary artery and pulmonary vein may be helpful in
assessing the possible roles of pulmonary atrial natriuretic
factor degradation and left atrial secretion. Finally, these
results show a substantial net increase in atrial natriuretic
factor across the heart, from 76 ± 24 pg/ml in the vena
cava to 177 ± 46 pg/ml in the aorta (p < 0.001).
Stimuli for release of atrial natriuretic factor: role of
increased left atrial pressure and wall stretch. Secretion
of atrial natriuretic factor increases in isolated rat heart prep-
arations if central venous pressure is elevated (29,32), and
removal of the atria results in a reduction in the diuretic and
natriuretic responses to acute elevation of central venous
pressure (31). These animal data suggest that increased in-
travascular volume, with concomitant atrial distension, re-
sults in the release of atrial natriuretic factor.
Our data in patients with a variety of cardiovascular dis-
orders and a wide range of atrial pressures show a positive
correlation between right atrial pressure and pulmonary ar-
tery atrial natriuretic factor concentration (p < 0.001)
(Fig. 1). A stronger positive correlation is seen between
pulmonary capillary wedge pressure and aortic atrial natri-
uretic factor concentration (p < 0.001) (Fig, 2). The positive
relation between left atrial diameter and atrial natriuretic
factor concentration also supports the hypothesis that in-
creased atrial pressure, with subsequent atrial distension,
results in atrial natriuretic factor release (Table 3). Fur-
thermore, the increment in plasma atrial natriuretic factor
concentration across the heart is significantly associated with
atrial pressures, implying a dynamic relation between atrial
pressure and atrial natriuretic factor secretion. Additional
support for this concept is found in six patients in whom
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centrations of atrial natriuretic factor (868 to 1,912 pg/ml)
have been reported in coronary sinus blood in four patients,
suggesting that it may be released into the circulation through
the coronary sinus (44). Our right atrial samples, however,
did not show greater variability than samples obtained at
other sites as might be expected if atrial natriuretic factor
secretion through the coronary sinus resulted in "mixing"
Figure 3. The effect of increased atrial pressure on plasmaatrial
natriuretic factor (ANF) levels in six patients. Leg elevation in-
creased mean right atrial pressure from 0.5 ± 1.1 to 3.2 ± 1.1
mm Hg (p = 0.01), and increased mean pulmonary capillary
wedgepressure from4.7 ± 1.7 to 7.3 ± 2.3 mmHg (p < 0.05).
The change in plasma atrial natriuretic factor concentration as-
sociated with increased atrial pressure is depicted in the inferior
vena cava (lVC), right atrium (RA), right ventricle (RV), pul-
monary artery (PA) and aorta (AO). *p < 0.05; **p < 0.01.
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maneuvers were performed to acutely increase atrial pres-
sure (Fig. 3). In each patient a modest change in atrial
pressures resulted, within minutes, in altered central atrial
natriuretic factor concentration.
Thus, the relation between atrial pressure and atrial na-
triuretic factor concentrations was observed during acute
alterations in atrial pressure as well as in patients with chronic
elevation of atrial pressure. These findings are all consistent
with the hypothesis that increased atrial pressure is a stim-
ulus for atrial natriuretic factor secretion in humans. There
is, however, variability in atrial natriuretic factor concen-
tration between individuals with equal atrial pressures. This
variability could be due, in part, to discordance between
intracavitary atrial pressure and the extent of atrial wall
stretch. The degree of wall stretch depends not only on
intracavitary atrial pressure but also on atrial diameter and
atrial wall elasticity. In addition, chronic circulatory failure
may result in alterations in baseline atrial pressure, atrial
diameter and atrial elasticity, as well as in tissue concen-
trations of atrial natriuretic factor. Future studies of the
dynamics of atrial natriuretic factor secretion need to be
directed toward a better understanding of these interactions.
Myocardial levels of atrial natriuretic factor. Atrial
natriuretic factor concentrations were determined in fresh
atrial myocardium from a patient with severe (class IV)
chronic congestive heart failure and found to be 37.2 to
41.8 J-Lg/g of wet tissue. The effect of chronic congestive
heart failure on myocardial tissue levels is unknown and
these concentrations cannot be construed as representative
of normal human myocardial levels. Although normal hu-
man atrial tissue levels are yet to be determined, tissue levels
have been reported to be 52.5 J-Lg/g in the left atrium and
86.8 J-Lg/g in the right atrium of the normal rat (25). Never-
theless, the data from one patient suggest that human atrial
natriuretic factor is found in both atria, and concentrations
in ventricular tissue are substantially lower.
Conclusions. The concept of a natriuretic-diuretic car-
diac hormone, released by elevation of atrial pressure, is an
attractive one. Such a negative feedback system would stim-
ulate diuresis in the setting of an expanded circulatory vol-
ume, thereby reducing intravascular volume. The hemo-
dynamic effects of release of atrial natriuretic factor from
the atrium may be further modified by central nervous sys-
tem reflexes, as well as by interactions between atrial na-
triuretic factor and other regulatory hormones such as al-
dosterone, renin and vasopressin. Further studies are needed
to establish the influence of atrial natriuretic factor on vol-
ume regulation in normal subjects, as well as in pathologic
conditions characterized by disordered volume regulation.
Our findings suggest that myocardial atrial natriuretic
factor is found principally in the atria and show that atrial
pressure is positively correlated with plasma concentrations
of atrial natriuretic factor. These data provide evidence that
atrial pressure may be an important determinant of atrial
natriuretic factor release in humans.
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